Castle Biosciences (CSTL) Cash from Operations (2018 - 2026)

Castle Biosciences has reported Cash from Operations for 9 years, with the latest figure at 15201000.0 in Q2 2026.

• Quarterly Cash from Operations fell 26.99% year-over-year to 15201000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 42634000.0 (down 31.77% YoY) and the FY2025 annual result came in at 64347000.0, down 0.8% from the prior year.
• Cash from Operations improved to 15201000.0 in Q2 2026 per CSTL's latest filing, from 22129000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 26931000.0 in Q4 2025 and troughed at 25439000.0 in Q1 2023.
• A 5-year average of 4166888.89 and a median of 613000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 490.2% in 2022, then soared 733.86% in 2024.
• Over 5 years, Cash from Operations stood at 6000000.0 in 2022, then surged by 409.78% to 18587000.0 in 2023, then soared by 31.09% to 24365000.0 in 2024, then climbed by 10.53% to 26931000.0 in 2025, then plunged by 43.56% to 15201000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 15201000.0, 22129000.0, and 26931000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.